Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2024 Earnings Presentation
19 slides from Hyphens Pharma International's earnings presentation, Feb 28, 2025
Slide 1: General Announcement: Result Briefing FY2024
2/27/25, 5:59 PM General Announcement::Result Briefing FY2024 GENERAL ANNOUNCEMENT::RESULT BRIEFING FY2024 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Title
Slide 2: 2/27/25, 5:59 PM General Announcement::Result Briefing FY2024 Total size =1787K MB
2/27/25, 5:59 PM General Announcement::Result Briefing FY2024 Total size =1787K MB https://links.sgx.com/1.0.0/corporate-announcements/M36VZ9MS8V1DIPC0/10b11575f7bfd62e2edc17cd27f430771d1ca594fd06757aa6c8ad7c4… 2/2
Slide 3: Results Briefing FY2024
RESULTS BRIEFING FY2024 28 February 2025 HYPHENS PHARMA INTERNATIONAL LIMITED
Slide 4: Disclaimer
DISCLAIMER • This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). • This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentati
Slide 5: Agenda
01 Results Overview 02 Business Updates 03 Financial Results Agenda 04 Business Outlook
Slide 6: Results Overview
01 Results Overview
Slide 7: Results Overview
Results Overview 195.4m 95.8m 2024 Revenue (SGD) +14.6% YoY 2H2024 Revenue (SGD) -0.1% YoY 10.9m 5.0m 2024 PAT (SGD) +26.5% YoY 2H2024 PAT (SGD) -1.5% YoY FOR 2024 REVENUE Specialty Pharma Proprietary Medical Hypermart Principals Brands and Digital +21.6% YoY +7.4% YoY +2.1% YoY
Slide 8: Business Updates
02 Business Updates
Slide 9: Business Updates
Business Updates Launch Ceradan® Advanced Hand Balm, in collaboration with A*STAR License Wynzora ® License Amenalief® Partner with 7-Eleven to from Maruho for offer Ocean Health® Cream for ASEAN countries from MC2 ASEAN supplements Therapeutics Jan 2024 Feb 2024 Mar 2024 May 2024 Jun 2024 Aug 2024
Slide 10: Financial Results
03 Financial Results
Slide 11: Overall Performance
Overall Performance Revenue FY2024 +14.6%YoY Profit after tax FY2024 +26.5%YoY (SGDm) CAGR 12.7% (SGDm) CAGR 15.2% 11.4 10.9 195.4 8.6 162.3 170.6 6.8 H2 H2 125.9 6.2 5.0 121 95.8 H1 H1 99.6 5.9 2020 2021 2022 2023 2024 2020 2021 2022 2023 2024
Slide 12: Performance by Geography
Performance by Geography Others, 11% Revenue by Geography Malaysia, SGDm 13% Singapore, 47% 2024 +6.9%, 90.9 Singapore 85.0 Vietnam, 29% +16.5%, 57.1 Vietnam 49.0 Others, 11% +49.7%, 25.8 Malaysia, Malaysia 17.2 10% Singapore, 50% 2023 +11.7%, 21.6 Others 19.4 Vietnam, 0.0 10.0 20.0 30.0 40.0 50.0 6
Slide 13: Performance by Segment
Performance by Segment • Group revenue grew 14.6% YoY Segment Revenue SGDm mainly driven by specialty pharma 250.00 principals. • Specialty pharma principals 200.00 segment grew 21.6% YoY. The 43.63 growth was contributed by all 150.00 42.75 43.22 27.55 geographies. 25.65 • Proprietary brands segmen
Slide 14: Segment Profitability
Segment Profitability EBIDTA by Segment EBITDA Margin (%) SGDm 20.0% 20.00 0.54 3.83 15.0% 2.31 15.00 0.24 15.5% 15.0% 1.48 13.9% 3.84 12.4% 12.4% 11.9% 1.13 10.0% 10.00 1.82 9.7% 9.5% 9.9% 9.3% 2.25 14.82 14.81 5.0% 3.6% 5.00 9.51 2.8% 8.15 6.04 1.2% 0.6% - 0.0% 2020 2021 2022 2023 2024 2020 2021 2
Slide 15: Rewarding Shareholders
Rewarding Shareholders We are pleased to propose a dividend of 1.5 Singapore cents (FY2023: 0.86 Singapore cents; 1H2023: 3.60 Singapore cents) per share for FY2024 Dividend Yield 18.00% 15.79% 16.00% 14.00% 12.00% 10.00% 8.00% 6.00% 5.36% 4.00% 3.36% 1.94% 2.27% 2.00% 0.00% FY2020 FY2021 FY2022 FY2
Slide 16: Business Outlook
04 Business Outlook
Slide 17: Business Outlook
Business Outlook Specialty Pharma Portfolio Medical Hypermart and Digital Proprietary Brands Further penetrate existing markets Continue growth momentum for key Continue to pursue the platform and channels products. Some products require development, while further greater efforts to regain market sh
Slide 18: Q&A
Q&A
Slide 19: Contact details
hyphens.com.sg hyphens-pharma-international/ 16 Tai Seng Street, Level 4, Singapore 534138
Hyphens Pharma International — FY2024 Earnings Presentation on 6ix